Alopecia, Androgenetic Clinical Trial
Official title:
A Randomized, Double-Blind, Vehicle-Controlled, Parallel Group, Multi-Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TDM-105795 in Healthy Male Subjects With Androgenetic Alopecia (AGA)
Multi-center, randomized, double-blind, vehicle-controlled, parallel group, multi-dose escalation study of TDM-105795 in male subjects, 18 to 55 years old, with Androgenetic Alopecia (AGA).
Protocol 239-11651-102 is a planned Phase 1 study entitled "A Randomized, Double-Blind, Vehicle-Controlled, Parallel Group, Multi-Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TDM-105795 in Healthy Male Subjects with Androgenetic Alopecia". Eligible subjects will be assigned to a sequential treatment cohort and will receive either one of the TDM-105795 solutions or the Placebo. The assigned test article will be applied once daily onto the scalp in the hair loss area (e.g., top of head and temple areas). All subjects will be treated with 1 mL/dose of test article with application to the scalp focusing on the regions that are bald and thinning. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01189279 -
Safety and Pharmacokinetics Study of New Formulation of Bimatoprost in Patients With Alopecia
|
Phase 1 | |
Completed |
NCT05296863 -
Adipose-derived Stem Cell Conditioned Media as a Novel Approach for Hair Regrowth in Male Androgenetic Alopecia
|
Phase 3 | |
Completed |
NCT02503852 -
STYLE -- A Trial of Cell Enriched Adipose For Androgenetic Alopecia
|
N/A | |
Completed |
NCT05802173 -
Study of TDM-105795 Following Topical Administration in Male Subjects With Androgenetic Alopecia
|
Phase 2 | |
Not yet recruiting |
NCT03154528 -
Role of Vitamin D in Androgenetic Alopecia
|
||
Terminated |
NCT02676310 -
Safety, Tolerability, and Pharmacokinetics of Bimatoprost in Men With Androgenetic Alopecia (AGA)
|
Phase 1 | |
Recruiting |
NCT05910450 -
A Study to Evaluate the Efficacy and Safety of Clascoterone Solution in Treatment of Male Pattern Hair Loss
|
Phase 3 | |
Completed |
NCT01325337 -
Safety and Efficacy Study of Bimatoprost in the Treatment of Men With Androgenic Alopecia
|
Phase 2 | |
Not yet recruiting |
NCT02316418 -
Hairstetics™ Anchoring System in Female Pattern Hair Loss (HAS-FPHL)
|
N/A | |
Recruiting |
NCT06263413 -
Clinical Workflow Optimization Using Artificial Intelligence for Dermatological Conditions
|
||
Recruiting |
NCT05681897 -
Comparing Platelet-Rich Plasma (PRP) Centrifugation Methods on Thrombocyte Concentration and Clinical Improvement of Androgenetic Alopecia
|
N/A | |
Completed |
NCT01904721 -
A Safety and Efficacy Study of Bimatoprost in Men With Androgenic Alopecia (AGA)
|
Phase 2 | |
Completed |
NCT03004469 -
Study to Evaluate the Efficacy and Safety of P-3074 Topical Solution in the Treatment of Androgenetic Alopecia
|
Phase 3 | |
Recruiting |
NCT05914805 -
A Study to Evaluate the Efficacy and Safety of Clascoterone Solution in Treatment of Male Pattern Hair Loss (SCALP2)
|
Phase 3 | |
Completed |
NCT04913519 -
A Phase 1 Study of TDM-105795 Topical Solution in Male Subjects With Androgenetic Alopecia (AGA)
|
Phase 1 |